Clinical Trials at Carle Cancer Institute Normal

As of July 2026, 46 paid clinical trials are recruiting at Carle Cancer Institute Normal in Normal, Illinois. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

46 clinical trials at Carle Cancer Institute Normal

·Clear filters·↓ Download CSV

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

for Non Small Cell Lung Cancer

Drug: Osimertinib

146 locations incl. Birmingham

Sponsor: PrECOG, LLC.

Sex: All·Age: 18+

Code: NCT06538038·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

for Locally Advanced Adrenal Cortical Carcinoma

Drug: Cabozantinib

71 locations incl. La Jolla

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12+

Code: NCT06900595·Phase 2·Recruiting

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

245 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting

Apply to this trial

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for Endometrial Adenocarcinoma

Drug: Ipilimumab

137 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05112601·Phase 2·Recruiting

Apply to this trial

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

86 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06649812·Phase 2·Recruiting

Apply to this trial

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

for Locally Recurrent Skin Squamous Cell Carcinoma

Drug: Amivantamab

38 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07042295·Phase 2·Recruiting

Apply to this trial